F.D.A. Approves Genvoya, a New One-Pill Treatment for H.I.V.
The pill is expected to be less likely to cause kidney damage or loss of bone density, which have become problems for people with H.I.V. who survive into old age.
View ArticleF.D.A. Approves Genvoya, One-Pill Treatment for H.I.V.
The Food and Drug Administration approved a new one-pill H.I.V. treatment on Thursday with a new, apparently safer form of tenofovir, a powerful H.I.V. inhibitor.
View ArticleReport: Drug Maker Was Focused on Profits, Not Patients
The makers of a breakthrough hepatitis drug put profits before patients in pricing the $1,000 pill that's become a symbol of the excessive cost of medications, Senate investigators said Tuesday.
View ArticleClik here to view.
Curing Hepatitis C, in an Experiment the Size of Egypt
A new approach tested in Egypt could become the blueprint for providing cutting-edge medicines to the poor.
View ArticleGilead Faces Fights Over Hepatitis C and H.I.V. Drugs
The company may face legal action in Massachusetts unless it drops prices for its hepatitis C drugs. In California, it is being sued over patents for an H.I.V. treatment.
View ArticleEurope Investigates Safety of Gilead Leukemia Drug
European regulators have started a review into the safety of Gilead Sciences’ leukemia drug Zydelig over concerns about serious adverse events, including deaths.
View ArticleClik here to view.
Merck Wins Hepatitis C Drug Patent Claim Against Gilead
A jury upheld the validity of Merck patents in a dispute with Gilead Sciences, which could be forced to hand over a portion of the billions of dollars it has made on hepatitis C drugs.
View ArticleMorning Agenda: The Unsettling Acquisitiveness of Anbang
Goldman Banker in Document Leak Case Avoids Prison | Puerto Rico Fights for Chapter 9 Bankruptcy in Supreme Court
View ArticleGilead Ordered to Pay Merck $200 Million in Patent Dispute
A federal jury on Thursday ordered Gilead Sciences to pay for infringing two Merck patents related to a lucrative cure for hepatitis C.
View ArticleDiscounts on Hepatitis C Drug Dent Gilead’s Earnings
The maker of Harvoni, a treatment for hepatitis C, said sales of the drug fell 15 percent in the first quarter.
View Article